New Perspectives on Early Stage Hypertrophic Cardiomyopathy: Measuring What Matters

Affiliations

Editorial

Fraser C Goldie et al. Circ Heart Fail. 2024 Aug.

. 2024 Aug;17(8):e012093.

doi: 10.1161/CIRCHEARTFAILURE.124.012093. Epub 2024 Aug 1.

¹ School of Cardiovascular and Metabolic Health, University of Glasgow, Glasgow Cardiovascular Research Centre, United Kingdom.

No abstract available

Keywords: Editorials; cardiomyopathy, hypertrophic; hypertrophy, left ventricular; risk assessment; sarcomeres.

Conflict of interest statement

Dr Coats has received fees from Alnylam, Cytokinetics, Pfizer, and Roche Diagnostics. The other author reports no conflicts.

Quality of Life and Exercise Capacity in Early Stage and Subclinical Hypertrophic Cardiomyopathy: A Secondary Analysis of the VANISH Trial.
Ireland CG, Burstein DS, Day SM, Axelsson Raja A, Russell MW, Zahka KG, Pereira A, Canter CE, Bach RG, Wheeler MT, Rossano JW, Owens AT, Bundgaard H, Mestroni L, Taylor MRG, Patel AR, Wilmot I, Soslow JH, Becker JR, Giverts I, Orav EJ, Claggett B, Lin KY, Ho CY. Ireland CG, et al. Circ Heart Fail. 2024 Aug;17(8):e011663. doi: 10.1161/CIRCHEARTFAILURE.124.011663. Epub 2024 Aug 1. Circ Heart Fail. 2024. PMID: 39087355 Free PMC article. Clinical Trial.